Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
“Critics often dismiss bottom-up AI innovation as a case of ‘when you have a hammer, everything looks like a nail,’ Saad ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Andrea Barnes Andrea Barnes is a writer covering large cleaning appliances.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results